Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 9/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246943 | 0.84 | GRM2 (0.56) | KLKB1GRM2 | |
| SCHEMBL16246850 | 0.83 | KMT2A (0.49) | KLKB1NPC1LMNAALDH1A1MAPT | |
| SCHEMBL19471906 | 0.82 | KLKB1 (0.56) | KLKB1NPC1RAB9A | |
| SCHEMBL17785429 | 0.81 | GRM2 (0.53) | KLKB1GRM2 | |
| SCHEMBL4544356 | 0.81 | ALDH1A1 (0.57) | KLKB1NPC1LMNAALDH1A1MAPT | |
| SCHEMBL23747886 | 0.80 | BTK (0.49) | KLKB1NPC1LMNA | |
| SCHEMBL369164 | 0.80 | ALDH1A1 (0.48) | KLKB1NPC1LMNAALDH1A1MAPT | |
| SCHEMBL16246920 | 0.78 | KLKB1 (0.53) | KLKB1NPC1LMNAALDH1A1 | |
| SCHEMBL16246985 | 0.78 | NPC1 (0.72) | NPC1LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17785281 | 0.78 | GRM2 (0.50) | KLKB1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863713-B1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-01-25 | — | — | EP | disclosed |
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| EP-3224255-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-16 | — | — | US | disclosed |
| EP-3863713-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| CN-112839711-A | Phenyltetrazole derivatives as plasma kallikrein inhibitors | 勃林格殷格翰国际有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3224255-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| WO-2016083818-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| EP-2999697-A1 | HETEROCYCLIC DERIVATES | Kalvista Pharmaceuticals Limited (GB) | 2016-03-30 | — | — | EP | disclosed |
| WO-2014188211-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885NPC1 1147/4885LMNA 678/4885 |
| US-20210387963-A1 | PHENYLTETRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, SERPINB1 | KLKB1 1/4885NPC1 1262/4885LMNA 2145/4885 |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | KLKB1 2/4885NPC1 1620/4885LMNA 584/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | KLKB1 1/4885NPC1 1147/4885LMNA 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.